


contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The Commissioner is authorized to charge \$180.00 in accordance with C.F.R. § 1.17(p) to effect entry of this Information Disclosure Statement to Deposit Account 19-0733. Further, the Commissioner is authorized to charge any additional fees which may be required or credit any overpayment to our Deposit Account 19-0733.

Respectfully submitted,


Date: September 9, 2005

By:

A handwritten signature in dark ink, appearing to read "Michelle L. Holmes-Son", written over a horizontal line.

Michelle L. Holmes-Son
Registration No. 47,660

Customer No. 22907
Banner & Witcoff, Ltd.



Substitute for form 1449A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	09/889,325
Filing Date	December 31, 2001
First Named Inventor	Saori KITAO
Art Unit	1642
Examiner Name	C. YAEN
Attorney Docket Number	001107.00454

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-6,335,435	01/01/2002	Shimamoto et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		OVERBEEK, PA et al., "Transgenic Animal Technology: A Laboratory Handbook," Factors affecting transgenic animal production, pp. 96-98 (1994)	
		WALL, RJ. "Transgenic Livestock: Progress and Prospects for the Future," <i>Thenogenology</i> , Vol. 45, No. 1, pp. 57-68 (1996)	
		HOUDEBINE, L., "Production of pharmaceutical proteins from transgenic animals," <i>J. Biotech.</i> Vol. 34, No. 3, pp. 269-87 (1994)	
		KAPPEL CA et al., "Regulating gene expression in transgenic animals," <i>Curr Opin Biotech.</i> Vol. 3, No. 5, pp. 548-53 (1992)	
		CAMERON ER. "Recent Advances in Transgenic Technology," <i>Mol. Biotech.</i> Vol. 7, No. 3, pp. 253-65 (1997)	
		NIEMAN II., "Transgenic farm animals get off the ground," <i>Transgenic Res.</i> ; Vol. 7, No. 1, pp. 73-5 (1998)	
		MULLINS JJ. and MULLINS, L. "Transgenesis in Nonmurine Species," <i>Hypertension</i> , Vol. 22, No. 4, pp. 630-3 (1993)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/889,325
Filing Date	December 31 2001
First Named Inventor	Saori KITAO
Art Unit	1637
Examiner Name	C. YAEN
Attorney Docket Number	004276.00003

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MULLINS, JJ. et al., "Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene," <i>Nature</i> , Vol. 344, No. 6266, pp. 541-4 (1990)	
		HAMMER, R. et al., "Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human B2m: An Animal Model of HLA-B*57:01-Associated Human Disorders," <i>Cell</i> Vol. 63, pp. 1099-1112 (1990)	
		MULLINS, JJ. et al., "Expression of the DBA/2J Ren-2 gene in the adrenal gland of transgenic mice," <i>EMBO J</i> Vol. 8, No. 13, pp. 4065-4072 (1989)	
		TAUROG, JD. et al., "HLA-B27 in Inbred and Non-inbred Transgenic Mice," <i>J. Immunol.</i> , Vol. 141, No. 11, pp. 4020-3 (1988)	
		MULLINS, L and MULLINS, JJ. "Perspective Series: Molecular Medicine in Genetically Engineered Animals," <i>J. Clin. Invest.</i> , Vol. 98, No. 11, pp. S37-40 (1996)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.